Discovering IZUMO1R: A Potential Drug Target for Various Diseases

Target Name: IZUMO1R

NCBI ID: G390243

IZUMO1R

Discovering IZUMO1R: A Potential Drug Target for Various Diseases

IZUMO1R (FOLR4) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the T-cell antigen receptor (TCR) family and is involved in the immune response.

Recent studies have identified IZUMO1R as a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and gastrointestinal diseases.

One of the reasons for the interest in IZUMO1R as a drug target is its unique structure. IZUMO1R is a transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region contains a large extracellular domain that is involved in cell adhesion and signaling, while the transmembrane region is responsible for the protein's movement and interactions with other molecules. The intracellular region is responsible for the protein's interaction with DNA and other cellular components.

The unique structure of IZUMO1R has led to the development of various experimental strategies to study its functions. For example, researchers have used cell-based assays to study the protein's interactions with other molecules, such as cell signaling pathways, protein-protein interactions, and DNA-protein interactions. These studies have provided insight into the mechanisms that regulate IZUMO1R function and have identified potential drug targets.

Another reason for the interest in IZUMO1R as a drug target is its potential role in various diseases. IZUMO1R has been shown to be involved in the immune response, specifically in the regulation of T cell function. Studies have shown that IZUMO1R plays a role in the development and maintenance of T cell tolerance, as well as in the regulation of T cell activation and proliferation.

In addition to its role in T cell function, IZUMO1R has also been shown to be involved in the regulation of cell signaling pathways that are important for various cellular processes, including cell growth, apoptosis, and angiogenesis.

The potential clinical applications of IZUMO1R as a drug target are vast. For example, IZUMO1R has been shown to be a potential therapeutic target for the treatment of various gastrointestinal diseases, including inflammatory bowel disease, colorectal cancer, and pancreatic cancer. In addition to its potential use in these diseases, IZUMO1R has also been shown to be a potential target for the treatment of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, IZUMO1R is a protein that is expressed in various tissues throughout the body and is involved in the immune response. Its unique structure and potential role in the regulation of various cellular processes make it an attractive target for the development of new drugs for the treatment of various diseases. Further research is needed to fully understand the functions of IZUMO1R and to identify its potential clinical applications.

Protein Name: IZUMO1 Receptor, JUNO

Functions: Receptor for IZUMO1 present at the cell surface of oocytes (oolemma), which is essential for species-specific gamete recognition and fertilization. The IZUMO1:IZUMO1R/JUNO interaction is a necessary adhesion event between sperm and egg that is required for fertilization but is not sufficient for cell fusion. The ligand-receptor interaction probably does not act as a membrane 'fusogen'. Does not bind folate

The "IZUMO1R Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IZUMO1R comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets